DeCure for Neurodegeneration with brain iron accumulation 5
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for neurodegeneration with brain iron accumulation 5 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeurodegeneration with brain iron accumulation 5 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neurodegeneration with brain iron accumulation 5 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
WD repeat domain 45 (WDR45) — WDR45 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8KBX · 3.23 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 1997 case report describes a patient with aceruloplasminemia, a disorder of iron metabolism that causes neurodegeneration of the retina and basal ganglia. The patient had progressive extrapyramidal symptoms including blepharospasm, grimacing, and rigidity, with increased iron deposition in the brain and visceral organs. Treatment for 10 months with the iron chelator desferrioxamine decreased brain iron stores, prevented progression of the neurological symptoms, and reduced plasma lipid peroxidation. This is a single patient, with no control, and the outcome is described as prevention of progression rather than reversal of existing damage.
Neurodegeneration with brain iron accumulation (NBIA) is a group of rare hereditary disorders characterised by high brain iron levels. Fifteen causative genes have been identified, but only two code for iron-related proteins; for most NBIA forms, how iron contributes to pathogenesis remains unclear. The most common NBIA form is pantothenate kinase-associated neurodegeneration (PKAN). A 2013 review of the TIRCON project states that as of that date there is no proven therapy to halt or reverse PKAN or any other NBIA form. The absence of adequately powered randomised clinical trials is attributed not to a lack of therapeutic options but to the rarity of the disease, the lack of patient registries, and the fragmentation of therapeutic research worldwide.
A 2019 review of NBIA models notes that experimental models that fully recapitulate the human phenotype are lacking, and knowledge of the pathogenesis of iron deposition remains scarce. A separate 2014 review on postoperative cognitive dysfunction speculates that iron accumulation may be an important mechanism and that iron chelator neuroprotection might provide a new target, but this is not tested in NBIA patients.
What is still missing: adequately powered randomised clinical trials for any NBIA form, patient registries to enable such trials, and experimental models that accurately reproduce the human disease to clarify how iron causes neurodegeneration in most NBIA subtypes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Neurology · 1997 · 175 citations
Use of desferrioxamine in the treatment of aceruloplasminemia
AbstractAceruloplasminemia is a newly recognized autosomal recessive disorder of iron metabolism resulting in neurodegeneration of the retina and basal ganglia. We report here on the treatment of a patient who developed progressive extrapyramidal symptoms that included blepharospasm, grimacing, and rigidity associated with increased iron deposition in the brain and visceral organs. Treatment for 10 months with the iron chelator desferrioxamine decreased brain iron stores, prevented progression of the neurological symptoms, and reduced plasma lipid peroxidation. These data suggest that early treatment with this chelator may be useful in such patients to diminish central nervous system iron accumulation and to prevent or ameliorate neurological symptoms associated with neurodegeneration.
Pharmaceuticals · 2019 · 91 citations · open access
Neurodegeneration with Brain Iron Accumulation Disorders: Valuable Models Aimed at Understanding the Pathogenesis of Iron Deposition
AbstractNeurodegeneration with brain iron accumulation (NBIA) is a set of neurodegenerative disorders, which includes very rare monogenetic diseases. They are heterogeneous in regard to the onset and the clinical symptoms, while the have in common a specific brain iron deposition in the region of the basal ganglia that can be visualized by radiological and histopathological examinations. Nowadays, 15 genes have been identified as causative for NBIA, of which only two code for iron-proteins, while all the other causative genes codify for proteins not involved in iron management. Thus, how iron participates to the pathogenetic mechanism of most NBIA remains unclear, essentially for the lack of experimental models that fully recapitulate the human phenotype. In this review we reported the recent data on new models of these disorders aimed at highlight the still scarce knowledge of the pathogenesis of iron deposition.
Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) - an integrated strategy under FP7 to improve research, treatment, and care in neurodegeneration with brain iron accumulation
AbstractAims: Neurodegeneration with brain iron accumulation (NBIA) is a clinically and genetically heterogeneous group of rare hereditary neurodegenerative disorders characterized by high levels of brain iron. Many NBIA cases are characterized by early childhood onset and rapid progression to disability and death. The most frequent form of NBIA is pantothenate kinase-associated neurodegeneration (PKAN). Currently, there is no proven therapy to halt or reverse PKAN or any other form of NBIA. This is especially unfortunate as both the iron accumulation in NBIA and the biochemical defect in PKAN are predicted to be amenable to drug-based treatment. Thus, the absence of adequately powered randomized clinical trials is not due to a lack of therapeutic options but to the rarity of the disease, the lack of patient registries, and the fragmentation of therapeutic research worldwide.
The role of iron accumulation in postoperative cognitive dysfunction
AbstractBackground Postoperative cognitive dysfunction (POCD) is a common neurological complication after anesthesia and surgery,especially prevalent in the elderly.Iron accumulation in the brain is an initial cause of neurodegeneration,it gives rise to neuronal degeneration and necrosis by arousing oxidative stress.Objective This review aims to investigate the role of iron accumulation in POCD.Content The distribution of brain iron,iron metabolism protein function,the relationship of excessive iron levels in the brain and neurodegeneration,as well as the progress of iron accumulation in POCD are described in the article.Trend Iron accumulation may be an important mechanism of POCD,the neuroprotection of iron chelator is expected to provide new target for the management of POCD.
Key words:
Iron accumulation; Neurodegeneration; Postoperative cognitive dysfunction
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
